The group’s principal activity activities include developing and commercializing of novel biologic therapeutics, medical devices for cardiovascular and ischemic disease. The group’s products include Generx, Corgentin, and Genvascor, The group marketed its products under the trade names Generx(TM) Excellarate(TM). In the year 2005, the group acquired AG Group in the year 2005 and Tissue Repair Company in the year 2006.
The group operates from the United States. The group’s revenue in the year 2006 was $ 756,137.
